Ursodeoxycholic acid is increasingly adopted for the treatment of liver diseases like primary biliary cholangitis (PBC) and gallstones. The drug works by lowering cholesterol in bile and making bile less sticky, thus reducing damage to liver cells. It is prescribed to people with PBC, a chronic disease of the bile ducts, to improve liver function tests and slow disease progression. Growing prevalence of liver diseases globally is boosting the demand for ursodeoxycholic acid.

The global Ursodeoxycholic Acid Market is estimated to be valued at US$ 640.45 Mn in 2023 and is expected to exhibit a CAGR of 3.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Increasing incidence of primary biliary cholangitis (PBC) is one of the major drivers of the global ursodeoxycholic acid market growth. According to the U.S. National Library of Medicine, the age-adjusted prevalence of PBC is estimated to be between 40-400 per million population among adults and is more common in women. The disease has a peak onset between 40-60 years of age. Rising prevalence of PBC is leading to increased demand for its treatment with ursodeoxycholic acid. Moreover, growing awareness about early diagnosis and management of liver diseases is propelling the market growth.

Segment Analysis
The global ursodeoxycholic acid market is dominated by 250mg sub-segment, which accounted for more than 30% market share in 2023. 250mg ursodeoxycholic acid is commonly prescribed by physicians for treating liver diseases such as primary biliary cirrhosis. It helps dissolve bile in the liver and gallbladder, improving the flow of bile and reducing liver damage. This dosage of ursodeoxycholic acid is also easily available across pharmaceutical channels and e-commerce platforms, contributing to its large consumer base.

Key Takeaways
The Global Ursodeoxycholic Acid Market Size is expected to witness high growth over the forecast period of 2023 to 2030. The global Ursodeoxycholic Acid Market is estimated to be valued at US$ 640.45 Mn in 2023 and is expected to exhibit a CAGR of 3.5% over the forecast period 2023 to 2030.

Regional analysis: North America was the largest regional market for ursodeoxycholic acid in 2023. Higher prevalence of liver diseases and growing obese population prone to fatty liver disease has been driving the demand for ursodeoxycholic acid in the region. The United States held over 70% share of the North American market owing to well-established healthcare infrastructure and availability of advanced treatment options. Europe was the second largest regional market for ursodeoxycholic acid, led by Germany, France and the United Kingdom.

Key players analysis: Key players operating in the ursodeoxycholic acid market are Fender Musical Instruments Corporation, Gibson Brands, Ernie Ball Inc., GHS Strings, C. F. Martin & Company Inc., Dunlop Manufacturing, Inc., Dean Markley USA, Inc., Kistron Co., Ltd., Rotosound Manufacturing Ltd., and DR Handmade Strings. Fender Musical Instruments Corporation has a strong global footprint and offers a wide range of ursodeoxycholic acid dosages. Gibson Brands has a stronghold in North America and manufactures ursodeoxycholic acid capsules and tablets.

Get more insights on this topic:
https://www.writerscafe.org/naufancmi/blogs/The-global-Ursodeoxycholic-Acid-Market-Growth-Accelerated-by-Increasing-Adoption-in-Liver-Diseases-Treatment/213002/